209 related articles for article (PubMed ID: 19570652)
21. The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.
Kucinski A; Wersinger S; Stachowiak EK; Becker C; Lippiello P; Bencherif M; Stachowiak MK
Behav Pharmacol; 2015 Feb; 26(1-2):217-26. PubMed ID: 25485645
[TBL] [Abstract][Full Text] [Related]
22. Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.
Tajiri M; Hayata-Takano A; Seiriki K; Ogata K; Hazama K; Shintani N; Baba A; Hashimoto H
J Mol Neurosci; 2012 Nov; 48(3):473-81. PubMed ID: 22843252
[TBL] [Abstract][Full Text] [Related]
23. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.
Huang M; Li Z; Dai J; Shahid M; Wong EH; Meltzer HY
Neuropsychopharmacology; 2008 Nov; 33(12):2934-45. PubMed ID: 18418367
[TBL] [Abstract][Full Text] [Related]
24. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.
Carlsson ML
J Neural Transm Gen Sect; 1995; 100(3):225-37. PubMed ID: 8748668
[TBL] [Abstract][Full Text] [Related]
25. Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
Kelly MP; Stein JM; Vecsey CG; Favilla C; Yang X; Bizily SF; Esposito MF; Wand G; Kanes SJ; Abel T
Mol Psychiatry; 2009 Apr; 14(4):398-415, 347. PubMed ID: 19030002
[TBL] [Abstract][Full Text] [Related]
26. RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
Rajagopal L; Kwon S; Huang M; Michael E; Bhat L; Cantillon M; Meltzer HY
Behav Brain Res; 2017 Aug; 332():180-199. PubMed ID: 28373127
[TBL] [Abstract][Full Text] [Related]
27. In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs.
Bortolozzi A; Amargós-Bosch M; Adell A; Díaz-Mataix L; Serrats J; Pons S; Artigas F
Eur J Neurosci; 2003 Sep; 18(5):1235-46. PubMed ID: 12956722
[TBL] [Abstract][Full Text] [Related]
28. High 5HT2A receptor occupancy in M100907-treated schizophrenic patients.
Talvik-Lotfi M; Nyberg S; Nordström AL; Ito H; Halldin C; Brunner F; Farde L
Psychopharmacology (Berl); 2000 Mar; 148(4):400-3. PubMed ID: 10928313
[TBL] [Abstract][Full Text] [Related]
29. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Carlsson ML; Martin P; Nilsson M; Sorensen SM; Carlsson A; Waters S; Waters N
J Neural Transm (Vienna); 1999; 106(2):123-9. PubMed ID: 10226932
[TBL] [Abstract][Full Text] [Related]
30. Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition.
Waters KA; Stean TO; Hammond B; Virley DJ; Upton N; Kew JN; Hussain I
Behav Brain Res; 2012 Mar; 228(1):211-8. PubMed ID: 22189656
[TBL] [Abstract][Full Text] [Related]
31. Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.
Gacsályi I; Nagy K; Pallagi K; Lévay G; Hársing LG; Móricz K; Kertész S; Varga P; Haller J; Gigler G; Szénási G; Barkóczy J; Bíró J; Spedding M; Antoni FA
Neuropharmacology; 2013 Jan; 64():254-63. PubMed ID: 22824189
[TBL] [Abstract][Full Text] [Related]
32. Schizophrenia: a neurodevelopmental disorder--integrative genomic hypothesis and therapeutic implications from a transgenic mouse model.
Stachowiak MK; Kucinski A; Curl R; Syposs C; Yang Y; Narla S; Terranova C; Prokop D; Klejbor I; Bencherif M; Birkaya B; Corso T; Parikh A; Tzanakakis ES; Wersinger S; Stachowiak EK
Schizophr Res; 2013 Feb; 143(2-3):367-76. PubMed ID: 23231877
[TBL] [Abstract][Full Text] [Related]
33. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Bonaccorso S; Meltzer HY; Li Z; Dai J; Alboszta AR; Ichikawa J
Neuropsychopharmacology; 2002 Sep; 27(3):430-41. PubMed ID: 12225700
[TBL] [Abstract][Full Text] [Related]
34. M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain.
Habara T; Hamamura T; Miki M; Ohashi K; Kuroda S
Eur J Pharmacol; 2001 Apr; 417(3):189-94. PubMed ID: 11334850
[TBL] [Abstract][Full Text] [Related]
35. Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.
Amodeo DA; Jones JH; Sweeney JA; Ragozzino ME
Autism Res; 2014 Oct; 7(5):555-67. PubMed ID: 24894823
[TBL] [Abstract][Full Text] [Related]
36. 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats.
Padich RA; McCloskey TC; Kehne JH
Psychopharmacology (Berl); 1996 Mar; 124(1-2):107-16. PubMed ID: 8935805
[TBL] [Abstract][Full Text] [Related]
37. 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.
Ferguson MC; Nayyar T; Deutch AY; Ansah TA
Neuropharmacology; 2010; 59(1-2):31-6. PubMed ID: 20361986
[TBL] [Abstract][Full Text] [Related]
38. 16p11.2 deletion syndrome mice perseverate with active coping response to acute stress - rescue by blocking 5-HT2A receptors.
Panzini CM; Ehlinger DG; Alchahin AM; Guo Y; Commons KG
J Neurochem; 2017 Dec; 143(6):708-721. PubMed ID: 28948999
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition.
Semenova S; Geyer MA; Sutcliffe JG; Markou A; Hedlund PB
Biol Psychiatry; 2008 Jan; 63(1):98-105. PubMed ID: 17531208
[TBL] [Abstract][Full Text] [Related]
40. Acute and repeated administration of the selective 5-HT(2A) receptor antagonist M100907 significantly alters the activity of midbrain dopamine neurons: an in vivo electrophysiological study.
Minabe Y; Hashimoto K; Watanabe KI; Ashby CR
Synapse; 2001 May; 40(2):102-12. PubMed ID: 11252021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
